Evotec Completes DeveloGen Acquisition

The acquisition adds drug discovery alliances to Evotec's portfolio of core assets, including one with Boehringer Ingelheim worth up to €237 million in potential milestone payments.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories